Strong Quarterly and Full-Year Revenue Growth
Q4 2025 revenue $64.6M, up 45.2% year-over-year; total 2025 revenue $211.1M, up 27.2% versus 2024.
U.S. Motiva Adoption and Revenue
U.S. Motiva revenue for 2025 was $45.6M with Q4 U.S. Motiva sales of $17.3M; management reported ~20% augmentation market share exiting 2025 and expects U.S. to exceed 30% of sales in 2026.
Margin Expansion and Gross Profit
Q4 gross profit $45.5M representing 70.5% gross margin (200 basis points improvement vs prior-year quarter); full-year 2025 gross margin improved ~330 basis points vs 2024.
Profitability Trajectory — Adjusted EBITDA Turnaround
Q4 adjusted EBITDA was positive $5.5M versus a loss of $13.1M in Q4 2024 — an $18.6M year-over-year improvement; management expects adjusted EBITDA positive every quarter in 2026 and free cash flow positive in 2026.
Reduced Operating Loss and Strong Cash Position
Q4 net loss from operations was $3.9M, down 79% year-over-year; ending cash balance $75.6M, up $4.9M in the quarter and management states no need for additional capital.
Ambitious 2026 Financial Guidance
Company guided 2026 revenue of $264M–$266M implying ~25% growth year-over-year; expects 200–300 basis points of gross margin improvement and operating expenses of $195M–$200M.
New Product Momentum — Preserve and Mia
Minimally invasive portfolio gaining traction: Preserve available in 33 markets with >700 accounts; Mia exceeded its $8M–$10M 2025 guidance and more than doubled accounts year-over-year; management estimates global minimally invasive demand >$30M in 2026.
Commercial Traction and Account Growth
Since late-2024 launch, >1,500 accounts onboarded (global); dozens of high-volume surgeons and early U.S. surgeons report strong patient demand and practice volume expansion; plan to add up to 15 U.S. sales reps in 2026 to accelerate penetration.